Flexion Therapeutics (FLXN) Stock News
NASDAQ:FLXN - Nasdaq -
FLXN Latest News, Press Relases and Analysis
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Analyst Ratings For Flexion Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Flexion Therapeutics (NASDAQ:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ECHO, ACBI, HRC, FLXN; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Echo Global Logistics, Inc. (NASDAQ:ECHO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by The Jordan Company, L.P. for $48.25 per share in cash.If you are an Echo shareholder, click here to learn more
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.
/PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion...
Mentions: PCRX
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors...
Mentions: PCRX
Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira
/PRNewswire/ -- Ademi LLP is investigating Flexion (Nasdaq: FLXN), for possible breaches of fiduciary duty and other violations of law in its transaction with...
FLXN Stock Is Winning Big Today Ahead of Merger With Pacira
FLXN stock is surging upward today as the company announces a merger with fellow biopharma play Pacira, valuing the company at $450 million.
